耳鼻咽喉科・頭頸部外科89巻5号

2017年04月発行

増刊号 臨床力UP！　耳鼻咽喉科検査マニュアル Ⅵ　腫瘍の検査

4　染色体・遺伝子転座—唾液腺がんを中心に

著者： 稲垣宏¹ 齋田昂佑¹

所属機関： ¹名古屋市立大学大学院医学研究科臨床病態病理学

ページ範囲：P.291 - P.299

●目的

・腫瘍遺伝子診断

・治療方針の決定

・患者予後の推定


●対象

　染色体・遺伝子転座は主に腫瘍細胞で観察されるため，腫瘍病理診断の補助的検査として免疫染色とともに用いられる。耳鼻咽喉科・頭頸部外科領域の腫瘍としては，特に唾液腺腫瘍が多彩な組織像を示すため，病理診断が時に困難である。近年，多くの腫瘍特異的な染色体転座・遺伝子転座が唾液腺腫瘍に報告され，その有用性が高まっている。そのほか，軟部腫瘍や甲状腺腫瘍にも多くの染色体転座が報告されている。

参考文献

1）Ellis GL, et al：AFIP atlas tumor pathology. Tumors of the salivary gland：ARP Press, Annapolis Junction, MD, 2008, pp173-438

2）Tonon G, et al：t（11；19）（q21；p13）Translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 33：208-213, 2003

3）Fehr A, et al：A new type of MAML2 fusion in mucoepidermoid carcinoma. Genes Chromosomes Cancer. 47：203-206, 2008

4）Conkright MD, et al：TORCs：transducers of regulated CREB activity. Mol Cell 12：413-423, 2003

5）Fonseca FP, et al：Molecular signature of salivary gland tumors：potential use as diagnostic and prognostic marker. J Oral Pathol Med 45：101-110, 2015

6）Chen Z, et al：Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells. Oncogene 33：3869-3877, 2014

7）Jee KJ, et al：Genomic profiles and CRTC1-MAML2 fusion distinguish different subtypes of mucoepidermoid carcinoma. Mod Pathol 26：213-222, 2013

8）Moller E, et al：POU5F1, encoding a key regulator of stem cell pluripotency, is fused to EWSR1 in hidradenoma of the skin and mucoepidermoid carcinoma of the salivary glands. J Pathol 215：78-86, 2008

9）Okabe M, et al：MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. Clin Cancer Res 12：3902-3907, 2006

10）Bell D, et al：CRTC1/MAML2 fusion transcript in Warthin's tumor and mucoepidermoid carcinoma：evidence for a common genetic association. Genes Chromosomes Cancer 47：309-314, 2008

11）Nakayama T, et al：Clinicopathological significance of the CRTC3-MAML2 fusion transcript in mucoepidermoid carcinoma. Mod Pathol 22：1575-1581, 2009

12）Okumura Y, et al：Impact of CRTC1/3-MAML2 fusions on histological classification and prognosis of mucoepidermoid carcinoma. Histopathology 59：90-97, 2011

13）Anzick SL, et al：Unfavorable prognosis of CRTC1-MAML2 positive mucoepidermoid tumors with CDKN2A deletions. Genes Chromosomes Cancer 49：59-69, 2010

14）Persson M, et al：Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 106：18740-18744, 2009

15）Mitani Y, et al：Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma：Incidence, variability, and clinicopathologic significance. Clin Cancer Res 16：4722-4731, 2010

16）Mitani Y, et al：Novel chromosomal rearrangements and break points at the t（6；9）in salivary adenoid cystic carcinoma：association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clin Cancer Res 17：7003-7014, 2011

17）Mitani Y, et al：Novel MYBLI gene rearrangements with recurrent MYBLI-NFIB fusions in salivary adenoid cystic carcinomas lacking t（6；9）translocations. Clin Cancer Res 22：725-733, 2017

18）Brayer KJ, et al：Recurrent fusions in MYB and MYBL1 define a common transcription factor-driven oncogenic pathway in salivary gland adenoid cystic carcinoma. Cancer Discov 6：176-187, 2016

19）Skalova A, et al：Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene：a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 34：599-608, 2010

20）Wai DH, et al：The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells. Oncogene 19：906-915, 2000

21）Tognon C, et al：Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2：367-376, 2002

22）Tognon CE, et al：ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway. Cancer Res 71：1060-1070, 2011

23）Ito Y, et al：Mammary analogue secretory carcinoma of salivary glands：a clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion. Am J Surg Pathol 39：602-610, 2015

24）Drilon A, et al：What hides behind the MASC：clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma（MASC）. Ann Oncol 27：920-926, 2016

25）Katabi N, et al：Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts. Hum Pathol 46：26-33, 2015

26）Bahrami A, et al：An analysis of PLAG1 and HMGA2 rearrangements in salivary duct carcinoma and examination of the role of precursor lesions. Histopathology 63：250-262, 2013

27）Stenman G, et al：Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers. Oral Oncol 50：683-690, 2014